PROCEPT BioRobotics Corporation
PRCTNASDAQHealthcare● Active
$28.35
+$0.52(+1.87%)
Market Cap$1.6B
P/E Ratio—
52W High$66.85
52W Low$19.35
PROCEPT BioRobotics Corporation (PRCT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PRCT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
-$0.56
Est. -$0.55 · -1.8%
Revenue
$0.08B
Est. $0.08B · +3.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
PRCT reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.45 | — | — | — | $0.09B | — |
| ▼ Q2 FY2026 | Apr 29, 2026 | -$0.55 | -$0.56 | -1.8% | $0.08B | $0.08B | +3.2% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -$0.32 | -$0.53 | -65.6% | $0.08B | $0.09B | -18.5% |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$0.41 | -$0.38 | +7.3% | $0.08B | $0.09B | -11.1% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.41 | -$0.35 | +14.6% | $0.08B | $0.08B | -6.1% |
| ▲ Q2 FY2025 | Apr 24, 2025 | -$0.49 | -$0.45 | +8.2% | $0.07B | $0.07B | +5.7% |
| ▼ Q1 FY2025 | Feb 25, 2025 | -$0.34 | -$0.35 | -2.9% | $0.07B | $0.08B | -10.2% |
| ▲ Q4 FY2024 | Oct 28, 2024 | -$0.48 | -$0.40 | +16.7% | $0.06B | $0.07B | -12.6% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.45
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Miss
EPS Actual
-$0.56
EPS Est.
-$0.55
EPS Surpr.
-1.8%
Revenue
$0.08B
Q1 FY2026
Feb 25, 2026Miss
EPS Actual
-$0.53
EPS Est.
-$0.32
EPS Surpr.
-65.6%
Revenue
$0.08B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
-$0.38
EPS Est.
-$0.41
EPS Surpr.
+7.3%
Revenue
$0.08B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
-$0.35
EPS Est.
-$0.41
EPS Surpr.
+14.6%
Revenue
$0.08B
Q2 FY2025
Apr 24, 2025Beat
EPS Actual
-$0.45
EPS Est.
-$0.49
EPS Surpr.
+8.2%
Revenue
$0.07B
Q1 FY2025
Feb 25, 2025Miss
EPS Actual
-$0.35
EPS Est.
-$0.34
EPS Surpr.
-2.9%
Revenue
$0.07B
Q4 FY2024
Oct 28, 2024Beat
EPS Actual
-$0.40
EPS Est.
-$0.48
EPS Surpr.
+16.7%
Revenue
$0.06B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.05 | $0.05 | $0.05 | 5 |
| Q3 FY2028 | $-0.25 | $-0.24 | $-0.23 | 5 |
| Q2 FY2028 | $-0.31 | $-0.30 | $-0.29 | 6 |
| Q1 FY2028 | $-0.57 | $-0.55 | $-0.53 | 3 |
| Q4 FY2027 | $-0.07 | $-0.07 | $-0.07 | 2 |
| Q3 FY2027 | $-0.21 | $-0.21 | $-0.20 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.2B | $0.2B | $0.2B | 4 |
| Q3 FY2028 | $0.1B | $0.2B | $0.2B | 4 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 5 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 2 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 29, 2026 | -1.8% | $23.03 | $21.71 | -5.73% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -65.6% | $27.26 | $27.84 | +2.13% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +7.3% | $34.51 | $35.02 | +1.48% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +14.6% | $48.12 | $45.69 | -5.05% |
| ▲ Q2 FY2025 | Apr 24, 2025 | +8.2% | $55.70 | $52.56 | -5.64% |
| ▼ Q1 FY2025 | Feb 25, 2025 | -2.9% | $65.15 | $62.71 | -3.75% |
| ▲ Q4 FY2024 | Oct 28, 2024 | +16.7% | $68.77 | $91.00 | +32.33% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +3.9% | $63.32 | $62.00 | -2.08% |
Q2 FY2026-5.73%
Report Date
Apr 29, 2026
EPS Beat/Miss
-1.8%
Price Before
$23.03
Price After
$21.71
Q1 FY2026+2.13%
Report Date
Feb 25, 2026
EPS Beat/Miss
-65.6%
Price Before
$27.26
Price After
$27.84
Q4 FY2025+1.48%
Report Date
Nov 4, 2025
EPS Beat/Miss
+7.3%
Price Before
$34.51
Price After
$35.02
Q3 FY2025-5.05%
Report Date
Aug 6, 2025
EPS Beat/Miss
+14.6%
Price Before
$48.12
Price After
$45.69
Q2 FY2025-5.64%
Report Date
Apr 24, 2025
EPS Beat/Miss
+8.2%
Price Before
$55.70
Price After
$52.56
Q1 FY2025-3.75%
Report Date
Feb 25, 2025
EPS Beat/Miss
-2.9%
Price Before
$65.15
Price After
$62.71
Q4 FY2024+32.33%
Report Date
Oct 28, 2024
EPS Beat/Miss
+16.7%
Price Before
$68.77
Price After
$91.00
Q3 FY2024-2.08%
Report Date
Aug 1, 2024
EPS Beat/Miss
+3.9%
Price Before
$63.32
Price After
$62.00
Avg Beat Reaction+4.21%
Avg Miss Reaction-2.45%
Beat Rate5 / 8 quarters
Largest Move+32.33% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PRCT ends December
PROCEPT BioRobotics Corporation (PRCT) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $-0.56 — missing the analyst consensus of $-0.55 by -1.8%. The next PRCT earnings date is expected around September 1, 2026.
Each quarter, investors track PRCT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PRCT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PRCT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PRCT earnings · 5 questionsPROCEPT BioRobotics Corporation's next earnings report is expected around September 1, 2026. PRCT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PRCT historically reports after market close (AMC).
PRCT earnings datewhen is PRCT earningsPRCT next earnings datewhen does PRCT report earningsPRCT earnings calendar
▸ Source: FMP · PROCEPT BioRobotics Corporation SEC filings · US GAAP · PROCEPT BioRobotics Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026